Gene expression profiling was performed on 97 cases of infant ALL from Children's Oncology Group Trial P9407. Statistical modeling of an outcome predictor revealed three genes highly predictive of event-free survival (EFS), beyond age and MLL status: FLT3, IRX2 and TACC2.
MLLT3(AF9).
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The mechanism of leukemogenesis in infants, in both MLL-rearranged (MLL-R) and MLL-germline (MLL-G) cases, is a subject of intensive investigation and may differ from leukemogenesis in older children. [4] [5] [6] [7] [8] [9] [10] Studies of identical twins and retrospective analyses of neonatal blood spots have demonstrated that in many children, leukemia-initiating events may be acquired prenatally. 5 While several of the frequently recurring translocations (ETV6-RUNX1 and RUNX1-MTG8) associated with leukemia in older children have been demonstrated to arise in utero, they appear to be insufficient for leukemogenesis, which requires the acquisition of additional cooperating genetic lesions. This multistep process may account for the longer latency period before development of clinically overt leukemia. In contrast, in infants, latency is very short and MLL-R alone or in concert with only a few cooperating lesions may be sufficient for leukemogenesis. In support of this working hypothesis, whole genome studies of copy number variations or CGH arrays in MLL-R infant ALL cases have demonstrated a very limited number of DNA copy-number alterations, [4] [5] [6] in contrast to ALL arising in older children.
11
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From MLL belongs to the Trithorax Group (TRX-G) of proteins that regulate gene expression through chromatin association and modification. MLL binds to thousands of loci in the genome that are important for the regulation of hematopoiesis, cell signaling, and transcription. 7 Important downstream targets of MLL include genes within the Homeobox A (HOXA) cluster and MEIS1. These and other genes involved in transcriptional activation are partially regulated through histone H3K4 methylation by the SET domain of wild type MLL. In contrast, leukemogenic MLL fusion proteins lack a SET domain, but retain the ability to bind and methylate H3K4, causing persistent activation of target genes that contribute to a distinctive pattern of gene expression characteristic of MLL-R leukemias. 8 Thus, perturbed epigenetic regulation is likely to play a critical role in MLL-mediated leukemogenesis and further insights into this mechanism may provide new insights for therapeutic intervention. [8] [9] [10] 12, 13 The etiology and pathogenesis of infant ALL is complex and multifactorial, with critical in utero exposures, potential genetic susceptibility, MLL and other acquired genetic abnormalities, epigenetic dysregulation, and modifying influences all affecting the development and phenotype of the leukemia. 14 As patterns of gene expression may be reflective of these combined factors, we performed gene expression profiling in a cohort of 97 infant ALL cases accrued to COG Trial P9407, the largest infant cohort examined to date. We wished to determine if we could identify genes that might improve risk classification and outcome prediction in infant ALL, beyond the well-established factors of MLL status and patient age. We further wished to determine whether these profiles might provide new insights into this disease, reflect cooperating genetic lesions or pathways, and serve as potential diagnostic and therapeutic targets.
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Materials and Methods

Patient Selection and Characteristics
A total of 212 infants <365 days of age with ALL were enrolled onto COG P9407 study (NCT00002756, ClinicalTrials.gov) in 3 consecutive cohorts. A subset of 70 infants was enrolled between 1996 and 2000 on Cohorts 1 and 2 and another 142 infants were enrolled between 2001 and 2006 on Cohort 3. 15 Infants in Cohorts 1 and 2 were observed to have unacceptably high induction death rates leading to modification of the treatment regimen for Cohort 3. Pre-treatment leukemia specimens were available from 97 of 212 of the cases accrued to this trial, predominantly from cohort 3. 15 The pre-clinical and outcome characteristics of this cohort of 97 cases did not differ appreciably from the total 212 cases accrued (data not shown).
Treatment protocols were approved by the National Cancer Institute (NCI) and participating institutions through their Institutional Review Boards. MLL rearrangements and MLL partner genes were characterized using cytogenetic and molecular methods. 16 Informed consent for participation in these research studies was obtained from patients or authorized representatives.
An independent validation cohort consisting of 57 cases of infant ALL with a variety of MLL translocations, that had available U133_Plus_2 CEL files and outcome data, was provided by
Stam et al. 8 The criteria for selection of validation cases were the same as for COG P9407
samples.
Gene Expression Profiling
RNA was isolated from pre-treatment leukemic cell suspensions obtained from peripheral blood or bone marrow using TRIzol (Invitrogen, Carlsbad, CA). All samples had >70% leukemic blasts, with a median of 90% blasts. cDNA labeling, hybridization to U133_Plus_2 arrays (Affymetrix, Santa Clara, CA) and scanning were performed as previously described
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From (details in the Supplement). 17 The default RMA and MAS5 algorithms of Expression Console (v 1.1, Affymetrix, Santa Clara, CA) were used to generate and normalize signal intensities. Array experimental quality parameters for inclusion into the study included: scale factor <40, GAPDH M33197 3' intensity >15000 and GAPDH M33197 3'/5' ratio <3. Microarray gene expression data were available from an initial 54,504 probe sets after filtering to remove probe sets associated with sex-related genes, globins and controls, as previously described. 18 In order to minimize the impact of set effects in comparative analyses with the validation cohort, the 97 P9407 CEL files were combined with 73 infant cases from the validation cohort study 8 (including cases for which clinical data were not available) and 21 MLL-R cases from a previously reported pediatric study 17 prior to performing RMA. The final RMA-normalized dataset contained 191 cases from three separate studies. The P9407 gene expression data may be accessed via the National Cancer Institute caArray site (https://array.nci.nih.gov/caarray/project/EXP-520).
Statistical Analyses
Event-free survival (EFS) was calculated from the date of trial enrollment to either the date of first event (induction failure, relapse, second malignancy, or death) or last follow-up.
Outcome analysis was performed only on cases where a death did not occur within 7 days of trial enrollment. This eliminated two cases from P9407 and four from the validation cohort. All cases were retained for studies correlating gene expression profiles with age as a continuous variable, as outcome associations were not required for these analyses.
Three gene filtering methods based on the coefficient of variation (CV), the standard deviation (SD), and cancer outlier profile analysis (COPA) 19 were used to pre-select probe sets.
The union of the probes selected by these three methods was used for the further analyses. The 
Results
Clinical Features
The clinical and biologic features of the cohort of 97 infant ALL cases studied from COG Applying an age threshold of 90 days, the youngest 22 patients had significantly worse EFS than older infants ( Figure 1C ). Since patient age and MLL status were both observed to be significant factors in predicting EFS, we explored their combined impact. The Kaplan-Meier survival curve in Figure 1D displays the behavior of each age/MLL category. Not surprisingly, the 18 patients who were in the highest risk category for both variables (MLL-R and ≤ 90 days) had the poorest overall outcome ( Figure 1D ).
Gene Expression Profiling and Modeling Outcome Genes in the Full Cohort 1 0
To identify genes from the expression profiles that were significantly correlated with EFS and to model an outcome predictor in the full cohort of 97 infant ALL cases, we performed SAM analysis on the 430 potentially informative probe sets first determined by high CV, standard deviation, and COPA. The results of this analysis are provided in Table 2 . Applying a false discovery rate (FDR) cutoff of 1%, only 5 probe sets (derived from 4 genes) were retained in the analysis: TACC2, IRX2, IL1R2 and FLT3 ( Table 2) . Each of these genes retained prognostic significance for outcome prediction beyond or independent of patient age, and, all but FLT3 were significant for outcome prediction after adjusting for MLL status ( Table 2) . For all four genes, elevated expression was correlated with a poorer outcome. Interestingly, in pathways analysis The majority of "low risk" cases (10/11) defined by our predictive model using FLT3 expression were MLL-G, with the remaining case an MLL-AFF1. In order to rule out the possibility that low FLT3 expression was simply identifying all of the MLL-G cases, we analyzed all 17 MLL-G cases in this cohort to see how they performed in our predictive model ( Figure   2C ). Although 10 of the MLL-G cases were assigned to our "low risk" group, the remaining 7
were divided among "intermediate" (1) and "high risk" (6) 
Gene Expression Profiling and Modeling Outcome Genes in MLL-AFF1 Cases
For personal use only. on August 31, 2017. by guest www.bloodjournal.org Many of the genes that defined these distinct unsupervised clusters had associations with EFS and it was interesting to note that many of these cluster-associated probe sets (including IRX1, IRX2, NEGR1, TPD52 andVAT1L) were identified as genes predictive of outcome in supervised learning, as we built the model for outcome prediction for the MLL-AFF1 cases detailed below.
We next used supervised analysis to build a model for outcome prediction (EFS) in the infants with MLL-AFF1. As with the entire cohort, a SAM analysis was performed on the 214 potentially informative genes initially identified by CV, standard deviation and COPA.
Applying a FDR cutoff of 15%, 29 probe sets (representing 22 genes) were retained. Unlike the model built on the entire cohort, elevated expression of two of these probe sets correlated with a lower risk or a good outcome (Table 3A) and expression of 27 probe sets correlated with a higher risk or poorer outcome (Table 3B) . Among these 22 genes, five (EPS8, IL1R2, IRX2, MYRIP and TACC2) were previously identified when we built the predictive model for outcome in the entire infant ALL cohort.
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Using these 29 probe sets, we built an SPCA model which significantly separated 47
MLL-AFF1 cases into a low and a high risk group; this model was also predictive of outcome when tested against the independent validation cohort of 22 MLL-AFF1 cases from the Interfant-99 study (see details in the Supplement). Due to the known impact of patient age on outcome in infant ALL, we rebuilt the SPCA model with only those probe sets that retained significance after adjusting for age (the 9 probe sets derived from seven genes as noted in bold font, Table 3 The results for OS were comparable (P<.001; HR=5.61; Supplement Figure S4A ). Figure 4B illustrates We further examined the power of this predictive model relative to patient age in the MLL-AFF1 cases (using a 90-day cutoff). As shown in Figure 4C , the seven gene classifier effectively stratified the 36 infants >90 days of age into low versus high risk for EFS (P<.001, HR = 7.12), and for OS (P<.001, HR=11.2; Supplement Figure S4C ). All 11 infants While similar genes were identified through unsupervised clustering of MLL-AFF1 cases (Figure 3) , the seven-gene predictive model built through supervised methods was more precise for outcome prediction and effectively stratified risk in both the IRX-clustered and HOXAclustered cases ( Figure 3 ; Figure 4D ; Supplement Figure S4D ). The 17 "low risk" cases include (Figure 3 ) was generally associated with better outcome, the supervised EFS model distinguished 7 "high risk" cases, all of whom had events (contrasted with the 33% rate among the 15 HOXA cluster-type "low risk" cases).
Gene Expression Profiles Associated with Patient Age
Given the historical significance of patient age in infant leukemia and the striking association of outcome with patient age in our infant cohort, we sought to determine whether there was a significant correlation of gene expression and patient age in our cohort of MLL-AFF1 infant ALL cases. By treating leukemia cell gene expression as a continuous variable related to patient age in these infants, we found a dramatic change in gene expression patterns around 90 days of age, with a striking difference in gene expression patterns in infants ≤ 90 days versus those greater than 90 days in age. Figure 5 shows the top 43 probe sets (24 with increased expression associated with lower age and 19 with increased expression associated with higher age). Additionally, when we included 21 older children with ALL containing MLL-AFF1 translocations from our COG P9906 studies 17 in this analysis, they clustered with the older infants from COG P9407. This showed that infants >90 days of age have a gene expression signature more similar to older children than to infants ≤ 90 days of age.
Several genes associated with antibody production and B-cell maturation (e.g., IGJ, IGH, MS4A1) were expressed at higher levels in the leukemic cells from infants >90 days old, raising the possibility that MLL-AFF1 leukemias in older children might be arising in a more committed B cell progenitor than in younger infants. These older infants also had elevated expression of genes linked with NK cells and antigen stimulation (KLRB1, GNLY). In contrast, the younger Fig. S6B ).
Discussion
Our study of 97 infants with ALL (80/97 with MLL-R), accrued to COG Infant ALL Trial P9407, represents the largest cohort of infants reported to date to undergo gene expression profiling.
The 5-year EFS among these infants was very poor (41%), with superior survivals seen among infants with MLL-G, age >90 days, and low WBC counts at disease presentation. Expression profiling initially identified a number of genes that were significantly associated with EFS in the infant cohort (EPS8, TACC2, FLT3, MEIS1, IL1R2), including genes known to play a role in MLL-mediated leukemogenesis (MEIS1), tumor progression (STAB1), and therapeutic resistance in T-cell malignancies (KCNK12). 24, 25 Pathways analyses further demonstrated complex interaction patterns among these genes, all converging on the adaptor protein GRB2 which plays a critical role in tyrosine kinase and Ras cell signaling pathways (See detailed analysis in the Supplement; Fig. S5 ).
Our final model predictive of outcome in the entire infant ALL cohort included three key genes (FLT3, TACC2 and IRX2) that refined risk classification and outcome prediction beyond age and MLL status. Differential FLT3 expression was uniquely powerful, as low FLT3 expression identified a group of infants with a very favorable outcome. This group of infants, with a superior 5 year EFS of 100% (including 9 MLL-G and a one MLL-AFF1 case) had not been previously identified using any other classification algorithm. Conversely, the remaining
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From infants who were MLL-G (7/17) but had high FLT3 expression had an outcome similar to those infants with MLL-R (5-year EFS of 29% ± 17 versus 34% ± 5, respectively). High FLT3 expression is common in infants and children with MLL-R or high hyperdiploidy (>50 chromosomes) ALL, even in the absence of activating FLT3 mutations. 26 High expression of wild type FLT3 may act similarly to FLT3 mutants or internal tandem duplications by activating Ras/Raf/MAPK signaling pathways. 27 As leukemogenesis is a multistep process, high FLT3 activity may be a second "hit", in concert with MLL, to induce leukemogenesis in MLL-R infants.
In the development of the outcome predictor for the full cohort, our regression tree analysis further identified TACC2 and IRX2 as two important genes that significantly impacted infants with high FLT3 expression. Infants with high expression of either TACC2 or IRX2 had a significantly worse 5 year EFS of 15% as compared to 64% in infants with low expression of both genes. How the expression of these genes might be altered by underlying MLL rearrangements or other epigenetic changes in infant ALL is of interest. MLL functions as an epigenetic regulator during normal development by incorporating into a COMPAS-like complex that facilitates H3K4 methylation which is required for the transcriptional activation of developmental regulatory genes, including homeobox genes and target genes of the WNT signaling pathway. 7 When MLL is translocated, domains involved in methylation such as SET are lost and MLL fusion proteins recruit alternative histone methyltransferases, resulting in inappropriate histone modification and dysregulation of gene expression. 3 In addition to the potential activation of FLT3, this mechanism may underlie the activation of TACC2, a component of the chromatin modification machinery whose expression is regulated through binding of SMYD2 to the TACC2 promoter. 28 The SET domain on SMYD2 acts as a Polymorphisms of HSPA1A, HSPA1B, and other inflammatory or immunomodulatory genes, such as IL-8 or VCAN, have also been reported to influence susceptibility to cancer.
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In conclusion, we have developed gene expression classifiers that improve outcome prediction in infant ALL, beyond the well-established prognostic factors of patient age and MLL gene rearrangement status. Assessment of the expression levels of this relatively small number of genes that improve outcome prediction in the full cohort (FLT3, TACC2 and IRX2) or in the subset of MLL-AFF1 cases (NEGR1, VAT1L, IRX2, EPS8, TPD52, HLA-DQB1, HLA-DRB1) can easily be transitioned to a clinically useful diagnostic assay. Importantly, we can define those
infants who today have excellent responses to current therapies versus those who require the development of new approaches for cure, and, we can distinguish outcomes within the most predominant subset of infant ALL cases with MLL-AFF1 translocations. We have also found that higher expression of FLT3 identifies a group of MLL-G cases that has a poorer outcome than expected. Future inclusion of these infants in clinical trials testing FLT3 inhibitors, such as the COG Trial AALL0631 (NCT00557193) which randomizes infants with MLL-R to receive chemotherapy with or without the FLT3 inhibitor Lestaurtinib may improve their outcomes. The genes and pathways that we have identified not only serve as potential diagnostic targets, but also as potential therapeutic targets. As proposed by Stumpel et al, gene expression patterns that predict for poorer EFS in infant ALL, reflective of the aberrant epigenetic regulation in this disease, such as those defined in this study, suggest a role for demethylating agents in the treatment of infant ALL. 9 Our assessment of the role of these genes in pathways analysis has also identified key nodes that might be considered for targeted therapy, such as GRB2, that are centrally regulated by the high expression of multiple genes associated with a poorer outcome in infant ALL.
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